A clinical evaluation of clavulanate-potentiated amoxycillin in the management of moderate to severe respiratory tract infections.

Abstract

This study investigated the effects of clavulanate-potentiated amoxycillin in the management of moderate to severe respiratory tract infections. A total of 34 patients aged 10-70 years were studied to establish the clinical and bacterial efficacy of treatment and screened for unwanted effects and abnormal laboratory findings. Clavulanate-potentiated amoxycillin was given in dosages of 375 or 750 mg twice daily, orally, for a mean of 13 days (range 3-30 days). Patients were assessed at the end of 2 weeks and again on discharge from hospital (if later) for up to 6 months. Overall diminution in the number of symptoms was recorded at the end of the study; 78% of symptoms had disappeared after 2 weeks. The treatment proved highly effective in controlling respiratory tract infections in 94% of patients. The necessity for multiple drug therapy and parenteral administration was also avoided.

• Authors: C H Anyanwu, B U Umeh
• Journal: The Journal of international medical research (J Int Med Res) 1988 May-Jun Vol. 16 Issue 3 Pg. 210-5 ISSN: 0300-0605 [Print] England
• PMID: 3044873 (Publication Type: Clinical Trial, Journal Article)

Chemical References

• Clavulanic Acids
• Drug Combinations
• Amoxicillin-Potassium Clavulanate Combination
• Amoxicillin

Topics

• Adult
• Amoxicillin (adverse effects, therapeutic use)
• Amoxicillin-Potassium Clavulanate Combination
• Clavulanic Acids (adverse effects, therapeutic use)
• Clinical Trials as Topic
• Drug Combinations (adverse effects, therapeutic use)
• Female
• Humans
• Male
• Respiratory Tract Infections (drug therapy, microbiology, physiopathology)